Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|Oramed Announces Last Patient Treated in...||09/17/19|
|The Phase IIb double-blind, randomized, 90-day dose-ranging trial will assess the primary efficacy endpoint of reduction in HbA1c, as well as safety e...|
|Oramed to Present at Three Upcoming Conf...||09/03/19|
|NEW YORK , Sept. 3, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical c...|
|Date||2019-09-16 (BMO)||Est. (EPS/Rev.)||($0.23)/ 710K|
|Actual (EPS/Rev.)||/||EPS (TTM)||0|